Published Date: 17 Feb 2023
For people previously infected with COVID-19, analysis and assessment showed an 88% lower rate of hospitalization or death for at least 10 months compared to people who had no pre-existing disease .
Read Full NewsNeurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.
Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.
ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.
Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.
Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'
7 Pulmonology Headlines You Missed in January 2026
1.
AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI
2.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
3.
When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.
4.
No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.
5.
As pesticides and wildfires rise, kids with cancer need resources
1.
Uncovering the Hidden Symptoms of Parathyroid Cancer in Women
2.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
5.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation